Tafenoquine
Arakoda, Krintafel (tafenoquine) is a small molecule pharmaceutical. Tafenoquine was first approved as Krintafel on 2018-07-20. It is used to treat malaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Arakoda, Krintafel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafenoquine succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARAKODA | 60 Degrees Pharmaceuticals | N-210607 RX | 2018-08-08 | 1 products, RLD, RS |
| KRINTAFEL | GSK | N-210795 RX | 2018-07-20 | 1 products, RLD, RS |
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malaria | EFO_0001068 | D008288 | B54 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TAFENOQUINE SUCCINATE, KRINTAFEL, GLAXOSMITHKLINE | |||
| 2025-07-20 | ODE-201 | ||
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vivax malaria | D016780 | EFO_0007445 | B51 | 4 | 3 | 4 | 1 | 2 | 14 |
| Malaria | D008288 | EFO_0001068 | B54 | 2 | 3 | 2 | 1 | — | 8 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Falciparum malaria | D016778 | EFO_0007444 | B50 | — | 3 | — | — | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
| Babesiosis | D001404 | EFO_0007162 | B60.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tafenoquine |
| INN | tafenoquine |
| Description | N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine is an aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group. It is a member of (trifluoromethyl)benzenes, an aminoquinoline, an aromatic ether, a primary amino compound and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | Antimalarial |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 106635-80-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL298470 |
| ChEBI ID | — |
| PubChem CID | 115358 |
| DrugBank | — |
| UNII ID | 262P8GS9L9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,204 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
36 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use